

MEF2D Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 70	Source/Isotype: Rabbit	UniProt ID: #Q14814	Entrez-Gene Id: 4209
Product Usage Information		ApplicationDilutionWestern Blotting1:1000Immunoprecipitation1:50				
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		MEF2D Antibody recognizes endogenous levels of total MEF2D protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu168 of human MEF2D protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		peptide affinity chromatography. Myocyte enhancer factor 2D (MEF2D) is a member of the MEF2 family of transcription factors. In mammals, there are four MEF2C-related genes (<i>MEF2A, MEF2B, MEF2C</i> , and <i>MEF2D</i>) that encode proteins that exhibit significant amino acid sequence similarity within their DNA-binding domains and, to a lesser extent, throughout the rest of the proteins (1). MEF2 proteins contain a highly conserved N-terminal MADS-box domain, an MEF2 domain, and a more highly variable C-terminal transactivation domain (2). The MEF2 family members were originally described as muscle-specific DNA-binding proteins that recognize MEF2 motifs found within the promoters of many muscle-specific genes (3,4); however, more recently they have been found to play critical roles in other physiological processes, such as heart formation and nervous system development (5,6). As such, alterations in MEF2 protein levels can result in developmental and neurological disorders, as well as other diseases such as liver fibrosis and many types of cancer (7). Specifically, MEF2D expression in hepatocellular carcinoma (HCC) is associated with higher levels of proliferation and poor prognosis (8). MEF2D is also overexpressed in clinical colorectal cancer tissues, where its high expression correlates with metastatic process. Functional investigations show that MEF2D promotes cancer cell invasion and epithelial-mesenchymal transition (EMT) and that it is essential for certain microenvironment signals to induce EMT and metastasis <i>in vivo</i> (9). Alternatively, MEF2D may function as a tumor suppressor in lipo- and leiomyosarcoma, as decreased MEF2D activity results in increased cell proliferation and anchorage-independent growth (10). MEF2D may also act as a tumor suppressor in rhabdomyosarcoma, as loss of MEF2D expression results in inhibition of differentiation, increased cell proliferation, and increased anchorage-independent growth (11).				
Background References		1. Yang, S.H. et al. (1999) <i>Mol Cell Biol</i> 19, 4028-38. 2. Chen, X. et al. (2017) <i>Oncotarget</i> 8, 112152-65. 3. Brand, N.J. (1997) <i>Int J Biochem Cell Biol</i> 29, 1467-70. 4. Black, B.L. and Olson, E.N. (1998) <i>Annu Rev Cell Dev Biol</i> 14, 167-96. 5. Shalizi, A.K. and Bonni, A. (2005) <i>Curr Top Dev Biol</i> 69, 239-66. 6. Phan, D. et al. (2005) <i>Development</i> 132, 2669-78. 7. Pon, J.R. and Marra, M.A. (2016) <i>Oncotarget</i> 7, 2297-312. 8. Ma, L. et al. (2014) <i>Cancer Res</i> 74, 1452-62. 9. Su, L. et al. (2016) <i>Cancer Res</i> 76, 5054-67. 10. Di Giorgio, E. et al. (2013) <i>Mol Cell Biol</i> 33, 4473-91. 11. Zhang, M. et al. (2013) <i>Mol Cancer</i> 12, 150.				

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting IP: Immunoprecipitation

Cross-Reactivity Key H: Human

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.